Jerusalem, 10 April, 2026 (TPS-IL) — Israeli biopharmaceutical company Galmed Pharmaceuticals Ltd. announced a breakthrough development of a brain-penetrating formulation of its drug Aramchol, potentially advancing treatment for neurological diseases such as Parkinson’s and dementia.
Developed in collaboration with Nazareth-based Barcode Nanotech, the new formulation uses lipid nanoparticles to cross the blood-brain barrier, a major obstacle in treating central nervous system disorders. Early laboratory studies showed the drug reduced harmful protein aggregation linked to disease progression.
Galmed aims to begin early-stage clinical trials in Parkinson’s patients in the second half of 2026, pending regulatory guidance.